Trials / Completed
CompletedNCT03086239
A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a Japanese, multicenter, open-label, dose-escalation study. This is the first study to assess the safety and tolerability as well as explore the pharmacokinetics, pharmacodynamics and antitumor activity of rovalpituzumab tesirine in Japanese participants with advanced small cell lung cancer (SCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rovalpituzumab tesirine | Intravenous |
Timeline
- Start date
- 2017-04-28
- Primary completion
- 2018-01-30
- Completion
- 2018-08-20
- First posted
- 2017-03-22
- Last updated
- 2021-08-03
Locations
5 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03086239. Inclusion in this directory is not an endorsement.